Annexon, Inc. · NASDAQ:ANNX
Annexon — Technical Presentation (July 2026)
10 slides from Annexon's technical presentation, July 2026
Slide 1: Baseline Characteristics Associated With Loss of BCVA ≥15 ETDRS Letters in Geographic Atrophy, ARCHER Study
Baseline Characteristics Associated With Loss of BCVA ≥15 ETDRS Letters in Participants With Geographic Atrophy in the Phase 2 ARCHER Study Margaret Chang MD, MS1 On behalf of the ARCHER and ARCHER II Investigators 1 Retina Consultants Medical Group, Sacramento, CA
Slide 2: Disclosures
Disclosures • Speaker: Genentech, Annexon • Consultant: Genentech, AbbVie/RegenXBio, Astellas, Ocular Therapeutix, Oculis, Eyepoint, Boerhinger, Ollin, Outlook, Adverum, Annexon, RetinAI • Research support: Novartis, Eyebio, OcuTerra, Alexion, Outlook, Kodiak, 4DMT, Perceive, Kalaris, ONL, Character
Slide 3: GA is a Neurodegenerative Disease; Photoreceptor Synapses and Cells are Lost Before RPE
GA is a Neurodegenerative Disease; Photoreceptor (PR) Synapses and Cells are Lost Before RPE IPL Intact photoreceptors Declining photoreceptor Lesion synapses and cells furthest from lesion synapses and cells dysregulated as approach lesion loss of photoreceptors INL synapses and RPE Photoreceptor c
Slide 4: C1q Plays a Key Role in Neurodegeneration
C1q Plays a Key Role in Neurodegeneration Classical Complement Cascade C1q C1q tags functional synapses for removal in disease1 • Activates classical pathway • Attracts microglial cells • Drives neuronal death Amplifies inflammation C4 • Photoreceptor loss results in vision loss in AMD and tissue da
Slide 5: ARCHER: Phase 2 Trial Of The C1q Inhibitor Vonaprument (ANX007) in Dry AMD and GA
ARCHER: Phase 2 Trial Of The C1q Inhibitor Vonaprument (ANX007) in Patients with Dry AMD and GA Randomized, double-masked Included foveal and non-foveal lesions Stratified for lesion location and lesion size 12 months (n=270) Sham Vonaprument 5mg Vonaprument 5mg monthly or every other month monthly
Slide 6: Vonaprument Demonstrated Dose-Dependent Protection From Vision Loss as Measured by BCVA
Vonaprument Demonstrated Dose-Dependent Protection From Vision Loss as Measured by BCVA ≥15-Letter Loss PATIENTS WITH CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12 16.9% 8.7% 4.5% % Participants without % Participants ≥15-Letter BCVA Loss * 15/89 8/92 4/89 * Nominal p-value vs Sham^ --- .0994 .007
Slide 7: ARCHER: Vision Loss Occurred in Patients with Compromised BCVA at Baseline, but Still With Vision to Lose
ARCHER: BCVA ≥15-Letter Loss Occurred in Patients with Compromised BCVA Vision at Baseline, but Still With Vision to Lose • BCVA ≥15-letter loss did not occur in participants with BCVA at Baseline (Letters) baseline BCVA <44 letters • BCVA ≥15-letter loss less frequent in participants with baseline
Slide 8: ARCHER: Vision Loss Is Related to Baseline Lesion Location
ARCHER: BCVA ≥15-Letter Loss Is Related to Baseline Lesion Location PATIENTS WITH CONFIRMED BCVA ≥15-LETTER LOSS THROUGH MONTH 12 Sham Vonaprument EOM % Patients Vonaprument EM Nominal summary p- value vs. sham^ Vonaprument EM 0.0019 Vonaprument EOM 0.0254 ^Nominal p-value from a Cochran Mantel-Haen
Slide 9: Phase 3 Pivotal Program: Well-Informed Design and Powering
Phase 3 Pivotal Program: Well-Informed Design and Powering Leverages Phase 2 learnings and enriched for patients with higher risk of vision loss Primary analysis: Treatment masked 15 months through 24 months Vonaprument (ANX007) Monthly 5.0 mg/eye TOPLINE N=659 Randomized PIVOTAL DATA 2:1 EXPECTED S
Slide 10: Key Take-Away Points: Vonaprument in ARCHER and ARCHER II
Key Take-Away Points: Vonaprument in ARCHER and ARCHER II Vision loss in GA is driven by photoreceptor synapse and cell loss, which precede RPE atrophy C1q is an aberrant trigger for neurodegeneration in GA • C1q aberrantly activates classical complement to drive removal of photoreceptor synapses an